Baum, Hedlund, Aristei & Goldman, PC
Brent Wisner is an attorney and senior partner in the Los Angeles office of Baum, Hedlund, Aristei & Goldman, PC. A Los Angeles native, Brent is driven by a deep-rooted passion for using the law to help those who have been marginalized and hurt by large, and sometimes malicious, corporations. Brent has dedicated his practice to vindicating his client’s rights and holding wrongdoers accountable. He concentrates his practice on pharmaceutical class action litigation, toxic-tort injuries, whistleblower and qui tam claims, and consumer fraud litigation. Brent also oversees the firm’s Medicare Secondary Payer cases, representing Medicare providers who have lost taxpayer funds to pharmaceutical companies and other large defendants.
Brent is one of Baum Hedlund’s lead trial attorneys and manages a highly-trained team of attorneys on all aspects of the cases in his department. He takes pride in personally working up all facets of litigation—from briefing, expert discovery, through trial and, if needed, appeal.
Law360 named Mr. Wisner a “Titan of the Plaintiffs Bar” for, in part, his role as co-lead counsel in a complex trial that resulted in the first multi-million-dollar jury verdict against a brand-name drug-maker, GSK, holding it liable for injuries caused by a generic version of the drug Paxil. The case has been described as groundbreaking and likely to shape the landscape of pharmaceutical litigation for years to come. Also, because of this cutting-edge verdict, The National Law Journal recognized Brent and the firm as 2018 Elite Trial Lawyers and the first place winner in the category of Pharmaceutical Litigation.
One of the Leading Zantac Lawyers in the Country
In 2019, Brent and his colleagues filed lawsuits against the manufacturers of Zantac (ranitidine) alleging the popular heartburn medication contains a cancer-causing chemical (NDMA) at levels over 3,000 times greater than the FDA’s legal limit. The lawsuits were among the first of what will likely be many thousands. “Based on recent scientific findings, the levels of NDMA in Zantac are staggering,” says Wisner. “Considering how many people took Zantac in the U.S. since 1983, we are staring into the face of a public health crisis, and these defendants—in particular GSK and Pfizer—are to blame.”
The judge overseeing the multi-district litigation (MDL No. 2924) (where all of the cases filed in federal courts are consolidated) appointed Brent to the Practices and Procedures Team to help establish the protocols and methodology for litigating tens of thousands of cases in the years to come. Brent also serves as Co-Chair of the Zantac Litigation Group for AAJ – American Association for Justice.
Brent’s Appearances Discussing the Zantac Litigation
Brent Wisner Roundup Cancer Lawyer
Brent Wisner served on all the trial teams for the first three Monsanto Roundup trials. He served as co-lead trial counsel in two of the first three cases, delivering the opening and closing arguments, and cross-examining many of Monsanto’s corporate witnesses.
Brent Wisner in Monsanto Roundup Litigation:
The juries in the first three trials found that exposure to Monsanto’s Roundup weed killer caused the plaintiffs to develop non-Hodgkin lymphoma, awarding more than $2.424 billion in total damages.
Brent also holds a judge-appointed leadership role as administrator and co-lead counsel for the Roundup Judicial Council Coordination Proceedings (JCCP), which consists of hundreds of Roundup cases consolidated before the California Superior Court for the County of Alameda (state court). He also serves as Liaison Counsel to the Federal MDL-2741 (multi-district litigation) In Re: Roundup Products Liability Litigation for Roundup JCCP 4953 Alameda County.
Following the groundbreaking verdicts in the Monsanto trials, Brent has been honored with numerous awards and accolades in recognition of his skill in the courtroom: